To investigate the prognostic significance of HSD3B1 among individuals likely to be receiving ADT, we evaluated outcomes by HSD3B1 status in a cohort of 619 men with prostate cancer who developed metastases. Here, HSD3B1 is linked to prostate carcinoma.